Blog
RSS FeedPosted by Michael Wonder on 04 Jun 2020
Pierre Fabre receives European approval for Braftovi (encorafenib) in combination with cetuximab for the treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer
3 June 2020 - European approval is based on the Phase 3 BEACON CRC trial that demonstrated a significant improvement in ...
Posted by Michael Wonder on 04 Jun 2020
New small cell lung cancer drug accepted for TGA evaluation under Project Orbis
3 June 2020 - TGA has granted provisional designation for new drug lurbinectedin based on encouraging Phase 2 results and high ...
Posted by Michael Wonder on 03 Jun 2020
The FDA should not rush a COVID-19 vaccine
2 June 2020 - Vaccines are widely expected to offer the best way out of the COVID-19 pandemic. ...
Posted by Michael Wonder on 03 Jun 2020
Clarity Pharmaceuticals announces that the US FDA grants rare paediatric disease designation to Copper Cu 67 sartate for the treatment of neuroblastoma
3 June 2020 - Clarity Pharmaceuticals is pleased to announce that the U.S. FDA has granted rare paediatric disease designation to ...
Posted by Michael Wonder on 03 Jun 2020
Antimicrobial approvals are not bottlenecked by FDA
3 June 2020 - Sponsors seeking US FDA approval for anti-microbial drugs accessed expedited clinical testing and review programs at least ...
Posted by Michael Wonder on 03 Jun 2020
Law makers, government watchdog blast FDA for poor oversight of U.S. drug supply chain
2 June 2020 - A government watchdog blasted the FDA for fumbling its oversight of the safety of the U.S. ...
Posted by Michael Wonder on 03 Jun 2020
Hahn: FDA will make some changes amid COVID-19 permanent
1 June 2020 - The US FDA will look to permanently implement some of the processes and policies adopted in ...
Posted by Michael Wonder on 03 Jun 2020
Zoloft falls into shortage as virus anxiety strains supplies
2 June 2020 - Drug makers blame increase in demand and ingredient shortfall. ...
Posted by Michael Wonder on 03 Jun 2020
The CDC waited its entire existence for this moment. What went wrong?
3 June 2020 - Americans returning from China landed at U.S. airports by the thousands in early February, potential carriers ...
Posted by Michael Wonder on 03 Jun 2020
EMA weighs COVID-19 data transparency, not ready to resume full clinical data publication
1 June 2020 - In a response to officials at Germany’s IQWiG and the Cochrane Collaboration, EMA Executive Director Guido ...
Posted by Michael Wonder on 03 Jun 2020
Helsinn Group announces FDA approval of a new liquid formulation of Akynzeo (fosnetupitant/palonosetron) injection in the United States
2 June 2020 - Helsinn today announces that the U.S. FDA has approved the ready-to-dilute liquid formulation of Akynzeo (fosnetupitant/palonosetron) ...
Posted by Michael Wonder on 02 Jun 2020
Y-mAbs announces U.S. FDA acceptance of biologics license application for Danyelza (naxitamab) for the treatment of neuroblastoma for priority review
2 June 2020 - Y-mAbs Therapeutics today announced that the biologics license application for Danyelza (naxitamab) for the treatment of patients ...
Posted by Michael Wonder on 02 Jun 2020
European Commission approves Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma
2 June 2020 - EC approval based on data from first randomised Phase 3 trial (ICARIA-MM) to report results evaluating an ...
Posted by Michael Wonder on 02 Jun 2020
Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
2 June 2020 - Novartis today announced that it has received notice from the US FDA that the agency has extended ...
Posted by Michael Wonder on 02 Jun 2020
Health Canada advises Canadians to help support the continued supply of medications
1 June 2020 - Health Canada recognizes that drug shortages can have a significant impact on patients and health care ...